Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I spoke to Gerald this morning as he prepares for his Europe visit. The confidence and control he shows is the hallmark of a man (and his team) that has done his homework. We were discussing the implications of all the peer-reviewed independent research, for AMBS. Here is what he has to say:
"The bottom line is that no one will develop any product involving MANF commercially because we would be in a position to sue and get access to their full revenue stream. SO, anything that is published on MANF really ends up mostly belonging to the Company. Obviously, we would be much more interested in working with these researchers than suing them, so every new publication really validates our patent position and makes our patents more valuable to companies that would be interested in treating any of the diseases MANF appears to be indicated for."
As I have always maintained, AMBS had to make a start somewhere, like every other company. They have started at around $0.003 levels and are now 10X at ~$0.04 on virtually empty tank. The real AMBS story has not even reached chapter 1. AMBS has the potential (and is actually on its way) to be $50-100. Hope posters doubting AMBS's intentions with MANF are put to rest. LymPro, vital for Alzheimer's in its own right, was a strategic acquisition by AMBS. It was meant to be a bridge between AMBS-early-cash-strapped-days and MANF-clinical-trials. Such foresight and detailed planning wouldn't have been possible without Dr.Rubinfeld's guidance. He knows from experience the pitfalls for an emerging biotech, and was quick to devise a strategy where AMBS could (and has) hit the ground running. Every successful independent MANF research is only adding wood to the AMBS fire. MANF market, over all indications, is topping $30B now.
The rise of AMBS will be clean and swift. Stay tuned for BD-CLIA and MANF-CED announcements. It is time to put the foot down.
There has been a spate of posts moaning how AMBS has put PD and MANF on the bench and all AMBS is doing these days is handwaving at various other indications. Let me be very honest and blunt about this: At the present moment, LymPro is the lifeline for AMBS. LymPro is the engine that will keep AMBS running until it can begin MANF clinical trials in late 2014. Without LymPro, AMBS pps is worth zero dollars. It is LymPro that has kept AMBS at 3-4 cents and it is LymPro that will take AMBS pps to $0.5-1. The amount of work (patents, restructuring, recruitment, partnerships, clearing debts, research milestones) that AMBS has managed to complete in the last 10 months is phenomenal. Learn to give credit where it is due. AMBS has built a pipeline that now resembles like a fortress with multiple levels of defense. If its trials for any one (or more) indications fail, AMBS will be able to still keep moving forward. There is no guarantee that PD MANF trials will be successful. However, LymPro is what will keep AMBS pps from sinking. To be ignorant to the facts is one thing. But to refuse to learn is stupidity. So, before posting aimless nonsense, think. AMBS pps is primed for 5-30X growth. The CLIA partner will be announced in the coming days. MANF-CED partner will be announced soon after Gerald's Europe visit in the first week of September. Stay tuned.
Of course it is a financial transaction. But it is not funding as you repeatedly keep posting. If you owe someone $10K and your monthly expenses are another $10K, to see off the month you would need $20K. If you settle your $10K debt by selling some of your personal belongings, it does not mean you can see off the month. You still need another $10K.
AMBS has only settled a part of its loan. To continue research activities, AMBS need to raise $1-3M. And another $50-100M for human MANF trials.
According to what I am hearing AMBS is set to announce funding in the next 7-14 days. I am not sure if it is a secondary offering or a partnership. However, I can confirm that BD-LymPro analytical performance has been verified (stay tuned for an update from AMBS), I am hoping that BD decides to go forward with the CLIA study (which will fetch AMBS the necessary funds to continue research activities).
Even otherwise, a secondary offering would not be such a terrible event in the long run. Short term pps could drop to 2 cents, giving a tremendous opportunity to consolidate your positions. LymPro commercialization is only 90 days away and pps can hit $1 range. Looking forward to increasing my position by another 25% before AMBS announces funding.
This was not funding. It was settling debt via preferred D.
Funding will be announced in the next 7-14 days. By the way, MANF-CED partner has been identified. Formal announcement should be expected in the next 2-3 weeks.
It will be interesting to see the sensitivity/specificity in trials.
http://edition.cnn.com/2013/08/17/health/alzheimers-test-eye/index.html?hpt=hp_c4
I got the following email from MJFF:
Dear xxxxxxxx,
Thank you for your inquiry. The Therapeutic Pipeline Program pre-proposals are due on October 30, 2013. Funding decisions will be made later in the year.
If you are interested in applying, please visit: https://www.michaeljfox.org/research/grant-detail.php?id=9
If you are interested in reviewing research opportunities that have already been funded in the Therapeutic Pipeline Program, please visit the Funded Grants page and just put in the search criteria that you’d like to view: https://www.michaeljfox.org/foundation/funded-grants.php.
Sincerely,
Nazreen
Check out our FUNDING OPPORTUNITIES
Nazreen Laffir
Grants Administrator
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH
Phone: 212.509.0995 Ext. 252
___________________________________________________________
The answer is in all of us — get involved in speeding a cure today
MICHAELJFOX.ORG
According to my research and sources, AMBS will be announcing funding (continuation of the bridge-financing achieved in June 2013) in the next 14-21 days. I hope the news does not come before Aug 29. It will give me a chance to increase my investment by another 25%.
So far, two of my predictions (chill lift date, and Gerald's chill play) have been spot on. I am a little off (by JUST 200% !!!) on the pps targets. But hoping to nail funding date now. Expect to see +100M volume in September.
It was great to hear from the old man Dr. Rubinfeld. First time he has spoken since January OneMed conference. The seriousness and the impact he will have on AMBS cannot be overstated. AMBS story will pale Amgen. The FDA guidelines have changed for the better, over the last 20 years. It will not take AMBS 20 years to reach $100 pps.
Q3 is the defining moment in AMBS journey. Glad to be on it.
LymPro is expected to take the pps to $1 range. With MANF orphan indications, if FDA approved, AMBS could reach $45. I have not included Parkinson's market in my $45 evaluation. Do not forget "market reacts". Your job as an investor is to pick the winners while the market is sleeping.
Gerald has been true to his words in the blogs and presentations. MANF-CED partner for PD will be announced in the coming 3-4 weeks. LymPro-BD partnership for CLIA study expected any day now.
Shareholder Letter:
We are recruiting additional expertise to the Company to assist in forming a strong commercialization plan for LymPro so that we can begin generating revenue as quickly as possible, and expect to have announcements in this regard in the near future.
LymPro White Paper:
6.3 Near term
The Company intends to verify the clinical performance of the re-established assay in their contract GLP laboratory in a clinical performance Verification Study... Lastly, during this period of time, the Company expects to assemble a seasoned IVD executive management team to develop and commercialize the intellectual property as they execute on the present plan and expand the portfolio of activities.
There are no ambiguities in the various statements that have been issued by the company. Since the white paper is at least a month old, and cannot be updated with every little progress that the company makes, the readers are requested to read carefully and make correct inferences, before commenting. From the Shareholder Letter, it is clear that the company has already reached the "6.3 Near term" milestone. The next 6 months correspond to the Medium and hopefully, Long term milestones. This involves CLIA study and preferably in collaboration with pharmaceutical and biotechnology companies operating in the space, but alone if necessary.
Mr. Blackhawks, Your assessment is wrong. Please read LymPro white paper (now available on amarantus.com), sections 6.2-6.5, as well as the original white paper (if you have one) that was removed.
The analytical preference has been evaluated during Q2 and the results are expected anytime during Q3.
AMBS has already completed 6.2 and is carrying out 6.3 right now ( clinical performance of the assay and hiring launch team).
Commercialization should begin Q1 2014.
"We are recruiting additional expertise to the Company to assist in forming a strong commercialization plan for LymPro so that we can begin generating revenue as quickly as possible, and expect to have announcements in this regard in the near future."
This is exactly what I was hoping to hear some day. Glad the day has come. With LymPro on its way to the market (which means significant funds starting to come), AMBS will now shift its attention on the orphan indications and MANF-CED deal, just as I mentioned in my earlier posts. World's first blood-based biomarker for Alz with +96% accuracy... BD must be feeling absolutely over the moon for having LymPro under its belt.
I must admit that AMBS has the transparency and hitting milestone targets with clockwork precision that I have not seen in many of the big pharma on national exchanges world over. In just over 9 months, AMBS has brought LymPro back from the ashes. Just shows the intent and more importantly, the strong scientific foundation.
It would be interesting to know who AMBS has chosen to partner with for CED. My guess is Germany based BrainLab. Looking forward to the new recruits on the LymPro commercialization team. Dr. Rubinfeld is the mastermind pulling all the strings with his contacts in the biotech world. AMBS has done the hardest work over the past 10 months, with some more to be done over the next 2 months. The pps will take care of itself. Actually, the discussion of pps before Q4 2013 is futile. The company does not have much to show to expect a pps of any more than what it is right now. But as the company keeps hitting the milestones, the pps will move big. That is what is meant by "market reacts" and you need to be smart enough to recognize that. Those who say that the pps is too low and it can drop to $0.01 levels, I say let it drop. It will just give us a once-in-a-million-lifetimes chance of adding to our positions. Do you really think that after touching $0.01, the pps will stay at those levels? Yes, if the company's products and drugs fail, then yes, it deserves to go bankrupt. But LymPro, at least, is a success, and worth $500M. So, eventually, the stock will hit around $1.
Very excited about the upcoming MANF-CED partnership, MANF gene therapy data, and orphan data ...
The CLIA Program sets standards and issues certificates for clinical laboratory testing. CLIA defines a clinical laboratory as any facility which performs laboratory testing on specimens derived from humans for the purpose of providing information (1) for the diagnosis, prevention, or treatment of disease or impairment, and (2) for the assessment of health. An objective of the CLIA is to ensure the accuracy, reliability and timeliness of test results regardless of where the test was performed.
Under CLIA, tests that meet risk, error and complexity requirements are issued a CLIA certificate of waiver. In November 2007, The CLIA waiver provisions were revised by Congress to make it clear that tests approved by the FDA for home use automatically qualify for CLIA waiver.
"We are using BD's reagents in our development, as they are manufactured to the high standards necessary to meet the mass-scale distribution needed for LymPro to reach the over 400,000 individuals diagnosed and 5 million people living with Alzheimer's each year...We have just come through a very challenging period, where the very credibility of our Company was questioned; and we answered."
Job well done AMBS. Congrats to Gerald and his entire team for their decision to acquire LymPro from Provista. As I had mentioned in my earlier posts, AMBS was already planning for commercialization. Glad to know that one of the biggest names in diagnostics (BD) will take LymPro to the market, worldwide. Eagerly waiting to see how much BD will pay AMBS for CLIA. Personally, hoping to make 10X on my investment on this single milestone.
The market continues to sleep, as always. I will say this again that the market "reacts" to news. It is the job of a smart investor to be able to spot the right picks in a sleeping market, and be proactive. I hope the market keeps sleeping for another month. This will give me the opportunity to increase my share count by another 50%.
Remember that at the end of the day, it is the science that matters. Everything else is "details". If you are worried that the company does not have cash, wait and see. The science will come to AMBS rescue. You can't keep a good guy down, for long.
Gerald's honesty when he talks to shareholders in private and public, is remarkable. I have not seen him mislead, confuse or even half-lie to me. With Dr. Rubinfeld on board of advisors, I see AMBS in $2-$3 range by late 2015, thereby giving me a 40-60X. AMBS story will fade Amgen's.
Q3 is the defining moment in the AMBS journey. Glad to be on it.
Exonhit seems a reputed French biotech with its Tetanus diagnostic already in clinical use. Its Alz diagnostic is in semi-clinical use.
http://www.exonhit.com/diagnostics/portfolio
http://www.exonhit.com/diagnostics/portfolio#Internal_Development
We can surely speculate here on IHUB, all these "potential" AMBS competitors as acquisition/partnership targets for big pharma. However, this topic is better suited for some reputed analyst (or even Dr. Simon, AMBS) to shed more light on all these other biomarkers. I see that someone has asked Jason on seekingalpha to comment on these "new" biomarkers. Jason has not replied yet. Hopefully if more of us question him on this, he will probably discuss them in his future article. I spoke to Steve Rosenman (private discussion) for his views on AMBS. He is of the opinion that he likes AMBS pipeline and agrees that the upshot will be tremendous but they do not have anything to show (as of now).
I reiterate, Q3 2013 will be the defining point for AMBS. Orphan early-data, MANF-CED partner announcement is imminent. CLIA-LymPro will be announced late-Q3.
I had no internet access yesterday, and today I find the Chill lifted.
I know it is disgusting but I want to congratulate myself for calling out the Chill timing spot on. Some posters here told me there is no such thing as 90-day period. Hopefully, my other (and more important) DD will stand the test of time. GTLA
With no chill, watch out for the 100M volume days coming.
According to Jason, there seems to be financing about to happen in the near future. Hopefully the financing happens during a rally so that the pps does not take a serious hit. Also, if the financing happens after chill is lifted, then new investors who have been waiting to take positions, would chip in and that will cushion the pps from a substantial dip.
Hopefully, AMBS will get off it bum and accelerate to make LymPro the first blood-based Alz test. The self-imposed chill has delayed AMBS by a Q. The German research team could pip AMBS to the finish line if they have the required funds and a more efficient management. One of you should let Gerald know, if he does not know already, of the German findings. If these findings hold water, it will eat a chunk of AMBS market. AMBS must realize they are not alone trying to break into Alz diagnostics market. It will be interesting how much AMBS can manage to get for LymPro in-license now.
I quote Jason from SA:
The DTC chill is still in effect at some institutions. I think as soon as that comes off (I'm told the paperwork has been filed) I think you'll see the company finance and then, hopefully, start negotiating with partners for the advancement of MANF and LymPro.
Some of the posters here have misunderstood Gerald's chill play.
Any news that Gerald intends to communicate with the shareholders, will be done after the DTC lifts all chills in place. AMBS, since Q1 2013, has collected data for its MANF orphan indications as well as MANF delivery via gene-therapy, which AMBS thinks can be crucial for younger populations. These are two of the results that Gerald wants to share with the market. However, a chill on the shares obviously deters potential new investors. That is the reason why waiting until the chill is lifted, is the right/better/smart thing to do.
There is no orphan news that AMBS is expecting from the FDA. AMBS has not, IMO, applied for any orphan indications. The orphan data that AMBS has collected over the past 3 quarters is preliminary data on the basis of which AMBS could initiate its quest for orphan status for various indications. Hearing the presentations/webcasts, it looks like the data is extremely promising, (just like the MANF vs GDNF data that took AMBS from $0.005 to 0.195)
There is no JV news that AMBS is going to release, simply because it is too early to even expect a JV. The MANF-CED partnership is not a JV, and as per the various webcasts, is expected to materialize by late Q3.
The only other news to be released in the coming weeks is the BD Lympro results for the analytical performance study. This study (started late Q2, IMO) could be coming to a completion in the coming days/weeks. This study is the bottleneck for AMBS. If the results are positive, then, as Gerald emailed me, "this could lead to multiple partnerships for the company across the globe". As we all know, BD would be the front runner for CLIA deal with AMBS. However, this is not expected until mid-late Q3.
The release dates for all the above results/news are the company's prerogative. There is no third party (FDA, BD etc.) involved. Hence the "chill card", where the company would benefit (pps wise) the most if any such announcements are made in a chill-free period.
My funds will be available tomorrow. Hopefully the chill remains in effect at least until later tomorrow. The stock could gain 150-200%. It has been one long wait, especially for a pennystock. Its beginning to dawn.
Given the low stock price of around 3 cents, I was giving it a thought as to how can AMBS attract institutional investors that often have $5 threshold. As of now, the company’s pool of potential investors is grossly limited to only individual investors. Moreover, being under $2, the stock is not marginable, that further precludes margin-buyers from buying the stock.
Had the stock been trading around $3-4, a reverse-split would not be a bad choice. But at the present pps levels, I don't see that happening at all.
I do see the pps picture changing significantly with the upcoming milestones. I see that a successful LymPro CLIA launch could fetch AMBS about $400M that would take the pps to $1+
Those blaming the management for not doing enough do not realize how difficult it is for a start-up to raise funds, attract investors, uplist to a major exchange. Hats off to Gerald and his team on how far they have come along since Q4 2012.
Looking forward to DTC chill removal this week. My assessment is that this could take the pps to $0.07 levels at least. Now is the time, it is written on the wind.
Chills usually last 90 days. It has been around 100 days now. Chill lift is overdue. As per my DD, I had set the lifting to have happened last week. That did not happen. Gerald is already on record having said that the lift could come any day, which backs up my DD perfectly.
The fact that Gerald has not released any news on orphan data and MANF delivery via gene-therapy (which as Gerald spoke at OneMed, was supposed to have released during late Q2), it gels well with my "chill play" theory. I had a conversation with Russell Miller yesterday. From what I could sense, the company has gone in "calm before the storm" mode.
Getting mighty close now. The wait is (almost) finally over, after 8 months of ordeal during which the stock has tanked 86%. It was not easy to hold position but I had to remind myself of the science and the reputed BOA to reassure myself that AMBS is the real deal and could be one of my all time best investments. I have been able to transfer more funds to buy AMBS. I hope the chill lifting does not come before Wednesday when my funds get cleared. Desperate to cost average down to 0.04 before saying goodbye to under-50 cents, forever. When a stock has momentum and volume behind it, it usually balloons well past what the investors, analysts and company fundamentals might value the stock at. LymPro alone will take AMBS to $1-2.
Do not forget that after BD LymPro results are announced in the next few days, the next super-duper catalysts are MANF-CED partnership and LymPro CLIA funding, both of which should come during late Q3 according to the white paper. The fact that AMBS is hitting bulls eye with every milestone mentioned in the white paper, is creditable. Having Jason Napodano on their positive side is bloody good as well. I am also in touch with a few seeking alpha analysts to get their opinions and possibly seeking alpha write-ups. Stay tuned.
Sent a nasty, abusive email to Don Markley on Tuesday. That guy gets on my nerves. Anyway, he forward it to Gerald who replied yesterday. I will not quote him but here are the pointers:
1. The company has come a long way since Q4 2012.
2. Delisting from Berlin exchange was crucial.
3. FDA's push towards early diagonsis/prognosis has coincided perfectly with LymPro revival.
4. The company is looking forward to LymPro commercialization.
5. BD deal was the biggest victory for the company in 2013 (so far), since, apart from performing validation studies, it has the capability for a successful worldwide commercialization.
6. Financing and the sucky pps are not the immediate concerns to the company, contrary to what the shareholders think.
To me, 4 and 5 are the smoking guns. It is clear that AMBS is already looking beyond LymPro's effectiveness. It seems that LymPro phase-1 and phase-2 results establish its superiority over any other Alzheimer biomarker. That is why AMBS in not even worried about the BD results. AMBS is already planning commercialization.
Since AMBS is positive about BD results, it seems that AMBS has developed a close rapport with BD. Do not forget that according to Gerald AMBS has been working with BD for a few months now (even before AMBS-BD deal was announced). IMO, AMBS feels that there is no reason why BD would not want to pay AMBS for in-licensing LymPro for the CLIA study and the subsequent commercialization. A first-ever Alzheimer blood biomarker would be a great asset for any company to have under their belt.
Based on 4 and 5, IMO AMBS is confident that the financing issues will take care of itself (with CLIA fees that AMBS will receive). This will solve the PPS crisis as well.
When you consider the BOD, BOA, LymPro, MANF, orphan indications, BD, you will realize that at under-3 cents, you have hit a jackpot. Had the stock been trading at say 3 dollars, I would be doubtful whether AMBS is overpriced, can they make it, are they genuine, should I wait to enter etc..., But at 3 cents, the Wall Street is sleeping. This is your opportunity. Take it or leave it.
I spoke to Jason Napodano, and he confirmed that he deleted his AMBS tweet on "chill play", saying the tweet was too speculative for an analyst to be tweeting.
AMBS is all set for massive events. Miss the boat at your own bad luck. Chill usually lasts for 90 days. AMBS chill was placed around 18 April. Chill will be lifted any day now. See what lifting the Chill does to a stock:
http://www.universalbioenergy.com/index.php?option=com_content&view=article&id=195:universal-bioenergy-announces-the-dtc-lifts-the-chill-on-its-stock-and-resumes-full-electronic-trading-&catid=35:company-news&Itemid=79
http://globenewswire.com/news-release/2012/10/25/499885/10009807/en/Universal-Bioenergy-Stock-Jumps-33-33-On-High-Volume-for-Second-Day-Trades-8-15-Million-Shares.html
I repeat:
Chill will be lifted this week, most likely. If it does not happen, don't be disappointed, because all the necessary paperwork for lifting the chill has been submitted (in June) and now all that is left is for DTC to complete the formalities on its part before removing the chill. It usually takes DTC 90 days for the chill decisions. It is overdue now (Like the Royal Baby, it can come any day now !!). PPS expected to regain 0.06 levels.
IMO, Gerald will not be releasing any news of orphan data/financing/partnership/LymPro before the chill gets lifted. He will be playing the chill card first. With the chill removed and institutional investors free to take their positions, each of the other cards (orphan data/financing/partnership/LymPro) can move the stock big. IMO, Gerald is just waiting for the right time (chill lifting) to release the news. Some of the potential partners are just waiting for the chill to be lifted before they initiate formal agreements/deals.
Jason Napodano (on twitter) agrees with my views above.
The very fact that a small biotech like AMBS was able to get one of the biggest and most reputable diagnostic firms like BD on board for testing LymPro, should have been enough to judge on the potential of AMBS and the credentials of its board. The posters here that keep bashing AMBS, its pipeline and its board, have zero investment experience and zero ability to weed junk stocks from winning stocks.
A sincere advice to those who have invested or hoping to invest in AMBS: Do not be misled by some of the armchair experts here rambling about "0.015", "the trend remains down" and "AMBS will have the funds to do Lympro or MANF but not both" nonsense. You need to use your own brain cells to decide what are the risk/reward chances with AMBS. For me, this is a 40-60X opportunity, and I have invested accordingly the amount that I am prepared to risk. Read the white papers publicly available on AMBS website. Even if you are not convinced or your financial state deters you from investing in AMBS, you should keep AMBS on your radar and perhaps jump in later as AMBS prepares to make a series of positive announcements regarding orphan data/financing/partnership/LymPro results.
I am in regular touch with Gerald E. Commissiong, President & CEO, and the management is excited about their scientific results and preparing to update the shareholders in the next few days.
Brick is correct.
LymPro, NuroPro, CTE look-out, are, each of them, massive milestones with significant market opportunity. Gerald with his colonels, is covering all bases and building multiple levels of defense in case the MANF fortress were to fall. It is called being pro-active and smart.
Remember CLSN, that had only one drug in the pipeline which failed and the stock tanked from $10 to $0.08?? Or a suite of PD drugs like preladenant (Merck), CERE-120 (Ceregene), rasagaline (ADAGIO), Stalevo (STRIDE)??? ALL FOUR TRIALS FAILED.
As promising as MANF is, AMBS is making sure that one failure shouldn't affect the company going forward.
As Gerald told me last week, "Once we achieve our unpcoming LymPro milestone, we expect there will be a number of collaborations available to the Company across the globe."
Get ready for the un-Chill.
Some of my posts are getting deleted for exposing the lies of some posters. Hopefully, this post will survive.
Chill will be lifted this week, most likely. PPS expected to regain 0.06 levels.
IMO, Gerald will not be releasing any news of orphan data/financing/partnership/LymPro before the chill gets lifted. He will be playing the chill card first. With the chill removed and institutional investors free to take their positions, each of the other cards (orphan data/financing/partnership/LymPro) can move the stock big. IMO, Gerald is just waiting for the right time (chill lifting) to release the news.
Do not be misled by some of the recent posts rambling about "the trend remains down" and "AMBS will have the funds to do Lympro or MANF but not both" nonsense.
In a recent webcast, Gerald said...
"You think pennies, Mr. Charles, you get pennies. You think dollars, you get dollars."
I am glad I am a AMBS shareholder. They have some revolutionizing science (with results to back them up). Couldn't be more relaxed.
Emberlin, it won't fade. The chill is getting lifted by DTC next week. The price may not budge much. But the volume will start building up, from 2-4 times slowly.
A little bit on DTC chill...
It is a big deal for a company because a Chill significantly reduces the volume of trading activity in the marketplace.
It's also rather difficult to remove a chill as the DTC now requires a sponsoring participating broker-dealer to recommend they remove the Chill. You'll really need some good contacts to make this happen in an efficient manner. However, there are companies that can lobby to have your DTC eligibility reinstated. AMBS stock was DTC chilled during the third week of April. The trading volume in the subsequent months has seen a nearly 80% drop. DTC is considering AMBS's plea to remove the chill. All trading restrictions on AMBS are likely to be removed during the fourth week of July. The trading volume over the past week has seen a steady increase, sometimes as high as twice the daily average volume.
The stock price is expected to regain its pre-chill value of around $0.055 over the next few sessions.
Enjoy your 0.24. The stock touched 0.195 in January. WHY? LymPro was hardly the discussion point those days. As I said "expected" and "actual" are two different beasts. You will learn. See you at $1 at least. And do not reply.
You are right Joshua buddy. It has to do with the DTC chill about to get lifted.
My sources (which by the way have a terrible record) indicate that DTC might lift the chill on 22 July.
I expect the pps to jump 150% (0.052) by next mid-week.
Your 13k will be 13K*50 = 650K before Q3 ends. Just wait for the LymPro analytical performance results from BD. Cheers. And Congrats.
Whoever bought those 2M shares, is a lucky bastard. Each of those shares will be worth between 1-2 dollars once LymPro enters CLIA study. Smart people are buying at the right time.
By the way, the paperwork for lifting chills has been submitted. DTC is going to decide "any time now". Jason Napodano has tweeted.
Get ready for AMBS take-off.
HaHa
No buddy, I am not directing my wrath at you. I am just posting on the go. Not specific to anybody's comments. When I will want to kick your butt, I will let you know !!!
AMBS=40-60 times in the coming weeks.
Look, let us grow up. Gerald is not going to say "such-and-such thing is happening on so-and-so date".
The fact that he saying "in the next few weeks", is all that an investor needs to know to time his/her entry point. Gerald or any other CEO would be an idiot to say "few weeks" when things are years away. Do not forget that the Company has white papers with timelines. And so far the previous events have been right on the button. There is your clue, as to the whether the company is lying or not.
My investment philosophy is to ignore what other investors are doing/thinking. Ignore the financial state of the company involved as well. Just look at the science. Genuine results always triumph.
Look at CLSN, PPHM. Market was gaga over these two, but their results were never verified/audited by any 3rd party. They presented misleading data, the shares popped, the pop burst, lawsuits followed.
AMBS data has been verified by Swiss lab, independent study in China, and now BD will most likely give a thumbs up to LymPro.
I do not care if "seasoned investors" and "analysts" like Scott Matusow think AMBS is a SCAM. Good for me.
Not to mention the kick a BD-AMBS partnership will give to AMBS's reputation. BD is a world leader. They will take LymPro to every corner on earth. I think US Alz market is $500M (I am not sure). Guess what the Worldwide market might be? US sales alone will take AMBS stock to ~ $2. I am positive we are about to see ACAD type phoenix rise. In fact 10 times better than ACAD which has risen 11X for its PD diagnosis.
No wonder the co-founder of Amgen, Dr. Rubinfeld, has called AMBS's pipeline to be potentially the biggest success story of his 45 year career.
I really pity those who doubt AMBS potential. If I had a million dollars for investment, I would not hesitate buying AMBS. The stock will not go below 0.03. The only thing that will make it go to 0.01-0.02 is LymPro failure. Chances of LymPro showing negative results in analytical performance at BD, are ZERO. This study is being done to re-confirm the previous findings (98% sensitivity, 96 % specificity). After re-confirmation, CLIA will begin for which most likely BD will pay $500-800M.
In another ~30 days, LymPro will become the first successful Alz Blood Test.
Anybody here follow Scott Matusow? That guy thinks AMBS is a SCAM and he keeps digging at Jason Napodano. SM will be crying in 30 days.
It will more than triple. A positive analytical feedback for LymPro from BD will lead somebody (BD most likely) to conduct CLIA study. For CLIA study, BD will have to pay AMBS, most likely $500-800M. That is what Lilly paid for AmyVid, which is not even half as good as LymPro.
A positive analytical feedback for LymPro can catapult AMBS to 40-60X.
Gerald's reply to me yesterday:
I can't comment on who we are involved with, but I can say that LymPro is certainly starting to gain traction in the community after a hiatus after the corporate problems at Provista. There is sincere cautious enthusiasm among those who are aware of the program about its potential and I think everyone is awaiting the first sets of analytical performance data from BD in order to be able to begin working together in a meaningful manner. Once we achieve our next milestone there will be a number of collaborations available to the Company across the globe."
The positive tone in Gerald's comments indicate that AMBS is more than confident with LymPro commercialization. Do not forget that Jason Napodano recently commented:
"I think the company needs to make a decision on either MANF or LymPro because they can't afford to do both at once. Pick one, out-license the other, and move forward. AMBS is using BD as a CRO to validate the previous findings with LymPro. The upside is that BD is not just a CRO, they are a fully-integrated diagnostic company that can take LymPro all the way to commercialization. So if the validation work confirms the previous phase 1, then AMBS will be looking for another firm to conduct the CLIA study and commercialize the product. I'd be surprised if this firm is not BD, and BD will then pay AMBS for those rights. The good thing is that we don't have to wait long. Gerald said data is coming in the Q3 from the validation study."
I seems to me that AMBS is certain that BD will in-license LymPro and pay AMBS around $500-800M. That would put the PPS between $1.5 to $2. I think AMBS is convinced this will happen and they won't have to rely on any more dilution. Had this been not the case, AMBS would have already diluted more, since they are virtually running on empty tank since July. We should expect the results/financing/partnership real soon. That is why Gerald wrote that blog as well. If they do manage to pull some decent results/financing/partnership soon, it will only enhance Gerald's reputation as being honest to the shareholders. I think the blog just last week, was a master stroke. Connect the dots.
Looking at the videos, what strikes out is that Questionnaire-type screening of the general population for early detection of Alz, has been a failure. Such screening processes are qualitative in nature and prone to incorrectly distinguish Alz from other forms of dementia. This point has also been stressed by Gerald in all his webcasts.
I am more than ever convinced that LymPro is the real deal, a game changer. A reputable company like BD would have never agreed otherwise. It seems only a matter of time before BD announces to in-license LymPro sales worldwide. Jason Napodano, I salute your DD.